Skip to main content

Hackman Jeffrey S.'s Form 4 filing

Comera Life Sciences Holdings, Inc.CMRA · filed Sep 12, 2022

Accession no.
0001062993-22-019482
Filed
Sep 12, 2022
Trade date
Sep 9, 2022
Filing delay
3 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 1 non-derivative transaction. Open-market purchases total $98.1K. It was filed 3 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Hackman Jeffrey S.CIK 0001926254Director, Officer (See Remarks)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 9, 2022Common StockPPurchaseAcquired+47,600$2.06F1+$98,05647,600Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.00 to $2.10, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

Referenced by the price of 1 transaction in Table I.

Remarks

Chairman, President and Chief Executive Officer. Exhibit 24 Power of Attorney filed herewith.

Read the full filing on SEC EDGAR (opens in a new tab)